Valuation: Aquestive Therapeutics, Inc.

Market Cap 571M 507M 474M 432M 814M 54.9B 822M 5.73B 2.22B 28.07B 2.14B 2.1B 90.07B P/E 2026 *
-8.92x
P/E 2027 * -9.48x
Enterprise Value 493M 438M 409M 373M 703M 47.4B 709M 4.95B 1.92B 24.23B 1.85B 1.81B 77.77B EV / Sales 2026 *
9.88x
EV / Sales 2027 * 8.43x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
1 day+2.48%
1 week-2.78%
Current month-1.73%
1 month-15.43%
3 months+8.85%
6 months+10.17%
Current year-29.57%
1 week 4.42
Extreme 4.425
4.78
1 month 4.42
Extreme 4.425
5.48
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Sell

Chief Executive Officer

-25,000 0.0199%
09/09/26 Option

Head of Human Resources

4,586 0.0037%
09/09/26 Exercice

Executive/Senior Manager

26,250 0.0209%
Change 5-day change 1-year change 3-year change Capi.($)
+2.48%-2.78%-21.14%+225.00% 571M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average +0.04%-3.33%+22.34%+73.94% 369.78B
Weighted average by Cap. +0.42%-3.33%+30.51%+68.98%

Financials

2026 *2027 *
Net sales 49.93M 44.36M 41.4M 37.74M 71.17M 4.8B 71.84M 501M 194M 2.45B 187M 183M 7.87B 67.77M 60.21M 56.2M 51.22M 96.61M 6.51B 97.51M 680M 264M 3.33B 254M 249M 10.69B
Net income -63.62M -56.53M -52.76M -48.09M -90.69M -6.12B -91.53M -638M -247M -3.13B -239M -234M -10.03B -60.23M -53.51M -49.95M -45.52M -85.86M -5.79B -86.66M -604M -234M -2.96B -226M -221M -9.5B
Net Debt -78M -69.3M -64.68M -58.96M -111M -7.5B -112M -783M -303M -3.83B -293M -286M -12.3B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
02/10/26 $4.550 +2.48% 2,272,518
01/10/26 $4.440 -4.10% 2,686,549
30/09/26 $4.630 -0.86% 2,412,532
29/09/26 $4.670 -1.68% 1,708,401
28/09/26 $4.750 +1.50% 1,276,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.550USD
Average target price
9.333USD
Spread / Average Target
+105.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock